Detalhe da pesquisa
1.
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
JAMA
; 325(1): 50-58, 2021 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33300950
2.
GenCLiP 3: mining human genes' functions and regulatory networks from PubMed based on co-occurrences and natural language processing.
Bioinformatics
; 2019 Nov 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31681951
3.
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial.
Breast Cancer (Dove Med Press)
; 16: 223-231, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38628818
4.
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).
Clin Cancer Res
; 28(4): 637-645, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34810217